Did oral semaglutide show any benefit in early Alzheimer's trials?

No, the EVOKE and EVOKE+ trials showed no clinical efficacy for oral semaglutide in improving cognition or function in early Alzheimer's patients.

What were the results of the EVOKE and EVOKE+ trials for semaglutide?

The trials found no significant difference between oral semaglutide and placebo in cognitive or functional endpoints after two years, and biomarker reductions were minimal.

Will research continue into GLP-1RAs for Alzheimer's disease?

Yes, experts suggest that further research may explore GLP-1RAs in specific patient populations or as preventive therapy, despite the failure of oral semaglutide in recent trials.

Home / Health / Semaglutide Fails Alzheimer's Trials

Semaglutide Fails Alzheimer's Trials

20 Mar

•

Summary

Oral semaglutide showed no clinical efficacy in early Alzheimer's patients.
Key trial endpoints for cognition and function were not met.
Biomarker reduction was minimal and deemed clinically insignificant.

On March 19, 2026, Novo Nordisk presented disappointing full data from the EVOKE and EVOKE+ trials, revealing oral semaglutide's lack of clinical efficacy for early Alzheimer's disease. The trials showed no difference between the drug and placebo in cognitive or functional endpoints after 104 weeks. Biomarker reductions were observed but deemed clinically insignificant.

Despite prior real-world evidence suggesting benefits in metabolic conditions, the trials focused on patients with confirmed Alzheimer's pathology. This distinction, along with differing endpoints, may explain the negative results. Novo Nordisk discontinued the one-year extension periods and terminated the program in November 2025.

Panellists at the AD/PD 2026 conference suggested further research into GLP-1RAs for specific patient populations, such as those with comorbid metabolic disorders, or as preventive therapy. However, significant investment will be needed for future trials following this high-profile failure.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.